ES8207508A1 - Un procedimiento para la preparacion dle derivados de un acido hidroxamico. - Google Patents

Un procedimiento para la preparacion dle derivados de un acido hidroxamico.

Info

Publication number
ES8207508A1
ES8207508A1 ES501573A ES501573A ES8207508A1 ES 8207508 A1 ES8207508 A1 ES 8207508A1 ES 501573 A ES501573 A ES 501573A ES 501573 A ES501573 A ES 501573A ES 8207508 A1 ES8207508 A1 ES 8207508A1
Authority
ES
Spain
Prior art keywords
derivatives
procedure
preparation
hydroxamic acid
steroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES501573A
Other languages
English (en)
Spanish (es)
Other versions
ES501573A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of ES8207508A1 publication Critical patent/ES8207508A1/es
Publication of ES501573A0 publication Critical patent/ES501573A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES501573A 1980-04-24 1981-04-23 Un procedimiento para la preparacion dle derivados de un acido hidroxamico. Granted ES501573A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14352080A 1980-04-24 1980-04-24

Publications (2)

Publication Number Publication Date
ES8207508A1 true ES8207508A1 (es) 1982-09-16
ES501573A0 ES501573A0 (es) 1982-09-16

Family

ID=22504442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES501573A Granted ES501573A0 (es) 1980-04-24 1981-04-23 Un procedimiento para la preparacion dle derivados de un acido hidroxamico.

Country Status (9)

Country Link
EP (1) EP0039051B1 (cg-RX-API-DMAC10.html)
JP (1) JPS56167643A (cg-RX-API-DMAC10.html)
AT (1) ATE14423T1 (cg-RX-API-DMAC10.html)
DE (1) DE3171467D1 (cg-RX-API-DMAC10.html)
DK (1) DK156717C (cg-RX-API-DMAC10.html)
ES (1) ES501573A0 (cg-RX-API-DMAC10.html)
GR (1) GR74496B (cg-RX-API-DMAC10.html)
IE (1) IE53001B1 (cg-RX-API-DMAC10.html)
PT (1) PT72878B (cg-RX-API-DMAC10.html)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
US5068251A (en) * 1988-12-16 1991-11-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US5212189A (en) * 1991-12-17 1993-05-18 Warner-Lambert Company Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
US6335329B1 (en) 1997-12-19 2002-01-01 Amgen Inc. Carboxylic acid substituted heterocycles, derivatives thereof and methods of use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7053088B2 (en) 2002-05-22 2006-05-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2004014871A1 (en) 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7582631B2 (en) 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7429616B2 (en) 2005-07-15 2008-09-30 Board Of Regents, University Of Texas System Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CN101410370B (zh) 2006-03-29 2013-06-12 诺瓦提斯公司 基于异羟肟酸酯的选择性mmp抑制剂
ES2376396T3 (es) 2006-06-26 2012-03-13 Amgen Inc. Método para tratar aterosclerosis.
AU2007272830B2 (en) 2006-07-14 2011-07-28 Amgen Inc. Alkyne-substituted pyridone compounds and methods of use
ATE469144T1 (de) 2006-07-20 2010-06-15 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
AU2007275683B2 (en) 2006-07-20 2012-05-10 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
UA98955C2 (ru) 2007-03-23 2012-07-10 Амген Инк. Гетероциклические соединения и их применение
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
EA017939B1 (ru) 2007-12-03 2013-04-30 Новартис Аг Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
PT2268612E (pt) 2008-03-24 2014-11-13 Novartis Ag Inibidores de metaloprotease de matriz à base de arilsulfonamidas
AU2009333214B2 (en) 2008-12-17 2013-09-26 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010075869A1 (en) 2008-12-30 2010-07-08 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use
WO2010085968A1 (en) 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
US20100331306A1 (en) 2009-06-25 2010-12-30 Amgen Inc. Heterocyclic compounds and their uses
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
US8765940B2 (en) 2009-06-25 2014-07-01 Amgen Inc. Heterocyclic compounds and their uses
WO2010151735A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
KR20120050492A (ko) 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
BR112012004843A2 (pt) 2009-09-03 2019-09-24 Allergan Inc compostos como moduladores de tirosina cinase
KR20120049940A (ko) 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
CN102482265A (zh) 2009-09-04 2012-05-30 诺瓦提斯公司 用于治疗增殖性疾病的吡嗪基吡啶化合物
AU2010291206A1 (en) 2009-09-04 2012-02-23 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
ES2551002T3 (es) 2009-11-17 2015-11-13 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
JP2013514989A (ja) 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド 複素環式化合物およびその使用法
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
WO2011076744A1 (en) 2009-12-21 2011-06-30 Novartis Ag Disubstituted heteroaryl-fused pyridines
US8530648B2 (en) 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2011143495A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
MX2012013128A (es) 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
MA34300B1 (fr) 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
AU2011272862A1 (en) 2010-06-30 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
US8686137B2 (en) 2010-06-30 2014-04-01 Amgen Inc. Heterocyclic compounds and their uses
MX2012015143A (es) 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
CA2803259A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
JP2013530238A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Ｐｉ３ｋ活性の阻害剤としての複素環化合物及びその使用
WO2012003271A1 (en) 2010-07-02 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AU2011278825B2 (en) 2010-07-13 2012-09-20 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
DK2593452T3 (en) 2010-07-14 2017-04-24 Novartis Ag Heterocyclic compounds as IP receptor agonists
JP5650324B2 (ja) 2010-07-22 2015-01-07 ノバルティス アーゲー ２，３，５−三置換チオフェン化合物およびそれらの使用
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
RS54544B1 (sr) 2010-09-13 2016-06-30 Novartis Ag Triazin-oksadiazoli
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR083058A1 (es) 2010-09-20 2013-01-30 Envivo Pharmaceuticals Inc Compuestos de estructura de imidazotriazinona
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
EP2635565A1 (en) 2010-11-04 2013-09-11 Amgen Inc. 5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
WO2012068343A1 (en) 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
US20130261108A1 (en) 2010-12-20 2013-10-03 Irm Llc Compositions and methods for modulating farnesoid x receptors
WO2012087521A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
JP2014501261A (ja) 2010-12-23 2014-01-20 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
AU2012206527A1 (en) 2011-01-13 2013-08-01 Novartis Ag BACE-2 inhibitors for the treatment of metabolic disorders
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
WO2012130306A1 (en) 2011-03-30 2012-10-04 Elara Pharmaceuticals Gmbh Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
JP2014509616A (ja) 2011-03-31 2014-04-21 エーエムベーエルエーエム テクノロジー トランスファー ゲーエムベーハー 治療用イミダゾ［１，２−ａ］ピリジン化合物
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
WO2012177893A2 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US20140249139A1 (en) 2011-10-21 2014-09-04 Novartis Ag Quinazoline Derivatives
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
TW201348226A (zh) 2012-02-28 2013-12-01 Amgen Inc 作為ｐｉｍ抑制劑之醯胺
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
MX2014011970A (es) 2012-04-04 2015-05-12 Amgen Inc Compuestos heterociclicos y sus usos.
AU2013255470B2 (en) 2012-05-04 2015-09-17 Novartis Ag Complement pathway modulators and uses thereof
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
CN104520291A (zh) 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
EP2864322B1 (en) 2012-06-20 2016-04-27 Novartis AG Complement pathway modulators and uses thereof
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
ES2710491T3 (es) 2012-06-28 2019-04-25 Novartis Ag Moduladores de la vía del complemento y sus usos
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
BR112014032734A2 (pt) 2012-06-28 2017-06-27 Novartis Ag derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104684910B (zh) 2012-07-12 2016-10-12 诺华股份有限公司 补体途经调节剂及其用途
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
US20150210717A1 (en) 2012-09-13 2015-07-30 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
AU2016236187B2 (en) 2015-03-24 2020-05-21 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Inhibitors of Pseudomonas aeruginosa LecB
ES2770128T3 (es) 2015-04-30 2020-06-30 Recordati Ag Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
KR102706357B1 (ko) 2015-08-19 2024-09-11 비버스 인크. 제약 제제
CN105418480B (zh) * 2015-11-16 2019-05-10 青岛大学 2-(1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-1氢-吲哚-3-基)-n-羟基乙酰胺的制备和应用
CN119119017A (zh) 2015-12-18 2024-12-13 美国安进公司 烷基二氢喹啉磺酰胺化合物
MA44066A (fr) 2015-12-18 2018-10-24 Amgen Inc Composés sulfonamides de dihydroquinoline d'alcynyle
JP7161481B2 (ja) 2017-02-10 2022-10-26 ノバルティス アーゲー １－（４－アミノ－５－ブロモ－６－（１ｈ－ピラゾール－１－イル）ピリミジン－２－イル）－１ｈ－ピラゾール－４－オール及びがんの治療におけるその使用
US20200216434A1 (en) 2017-06-14 2020-07-09 European Molecular Biology Laboratory Benzofuran ureas or carbamates and heteroaromatic analogues thereof for use in therapy
AU2018285449A1 (en) 2017-06-14 2019-12-19 European Molecular Biology Laboratory Benzofuran amides and heteroaromatic analogues thereof for use in therapy
CN111032653A (zh) 2017-06-14 2020-04-17 欧洲分子生物学实验室 用于疗法的双环杂芳族酰胺化合物
CN111032654A (zh) 2017-06-14 2020-04-17 欧洲分子生物学实验室 用于疗法的双环杂芳族脲或氨基甲酸酯化合物
CN118146196A (zh) 2018-02-06 2024-06-07 海德堡大学 Fap抑制剂
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
ES2997190T3 (en) 2018-12-20 2025-02-14 Amgen Inc Heteroaryl amides useful as kif18a inhibitors
EP3898616B1 (en) 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
CA3147451A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4007753B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
JP2023501323A (ja) 2019-11-05 2023-01-18 へルムホルツ－ツェントルム・フューア・インフェクツィオーンスフォルシュング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 緑膿菌のバイオフィルム形成を標的とする二価のＬｅｃＡ阻害薬
AU2021210187A1 (en) 2020-01-22 2022-07-21 Benevolentai Bio Limited Pharmaceutical compositions and their uses
JP2023511170A (ja) 2020-01-22 2023-03-16 ベネボレントエーアイ バイオ リミティド 医薬組成物及びその使用
KR20230011932A (ko) 2020-04-14 2023-01-25 암젠 인크 신생물 질환의 치료를 위한 kif18a 저해제
WO2021234181A1 (en) 2020-05-22 2021-11-25 Universität Heidelberg Use of fap inhibitor in a method of diagnosis
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
CA3183948A1 (en) 2020-06-10 2021-12-16 Amgen Inc. Heteroalkyl dihydroquinoline sulfonamide compounds
WO2022043465A1 (en) 2020-08-26 2022-03-03 Max Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Inhibitors of no production
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
US20220211883A1 (en) 2020-12-17 2022-07-07 Trustees Of Tufts College Fap-activated radiotheranostics and uses related thereto
TW202325276A (zh) 2021-10-29 2023-07-01 德商艾斯巴赫生物有限公司 結合至新穎異位結合位之病毒解旋酶抑制劑
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy
CN119365198A (zh) 2022-05-02 2025-01-24 艾斯巴赫生物有限公司 ALC1抑制剂的用途和与PARPi的协同作用
WO2024022332A1 (en) 2022-07-26 2024-02-01 Shanghai Sinotau Biotech. Co., Ltd Fap inhibitors
TW202517632A (zh) 2023-07-12 2025-05-01 德商Ｈｍｎｃ控股有限公司 氘代1,3二氫-2h-吲哚-2-酮衍生物
CN120202191A (zh) 2023-09-12 2025-06-24 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
WO2025055942A1 (en) 2023-09-12 2025-03-20 Shanghai Sinotau Biotech. Co., Ltd Inhibitors of prostate specific membrane antigen and use thereof
WO2025088087A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
WO2025088175A1 (en) 2023-10-25 2025-05-01 Eisbach Bio Gmbh Alc1 inhibitors for use in treating cancer by potentiating the effects of several classes of approved cancer drugs
WO2025093706A1 (en) 2023-10-31 2025-05-08 Eisbach Bio Gmbh Alc1 inhibitors alc1i-1 and alc1i-2 for use in treating pancreatic cancer by potentiating the effect of irinotecan
WO2025252850A1 (en) 2024-06-06 2025-12-11 Helmholtz-Zentrum für Infektionsforschung GmbH Thiourea based derivatives are novel antimicrobials against a. baumannii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081993A (en) * 1963-04-17 1967-09-06 Ici Ltd Difluoramino compounds
US3336194A (en) * 1963-04-30 1967-08-15 Merck & Co Inc Indolyl acid amides
US3417096A (en) * 1965-07-01 1968-12-17 Bristol Myers Co Certain 5(1-benzoyl-3-indolylmethyl) tetrazoles
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
NO134946C (cg-RX-API-DMAC10.html) * 1970-09-09 1977-01-12 Ciba Geigy Ag
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents

Also Published As

Publication number Publication date
DE3171467D1 (en) 1985-08-29
PT72878B (en) 1983-03-29
GR74496B (cg-RX-API-DMAC10.html) 1984-06-28
ATE14423T1 (de) 1985-08-15
DK182081A (da) 1981-10-25
EP0039051A3 (en) 1982-05-26
EP0039051B1 (en) 1985-07-24
PT72878A (en) 1981-05-01
EP0039051A2 (en) 1981-11-04
IE810899L (en) 1981-10-24
DK156717C (da) 1990-02-19
JPS56167643A (en) 1981-12-23
IE53001B1 (en) 1988-05-11
JPH04982B2 (cg-RX-API-DMAC10.html) 1992-01-09
DK156717B (da) 1989-09-25
ES501573A0 (es) 1982-09-16

Similar Documents

Publication Publication Date Title
ES8207508A1 (es) Un procedimiento para la preparacion dle derivados de un acido hidroxamico.
FR2446822A1 (fr) 6-oxodecahydroquinoleines
SE425299B (sv) Forfarande for skerning av en kropp av ett material som er vesentligen oledande
DE3772015D1 (de) Chinolinverbindung.
AR217944A1 (es) Procedimiento para hidroformilar un compuesto alfa-olefinico,para producir un compuesto aldehidico o una mezcla de ellos
FR2361899A1 (fr) Nouveaux aminoethers de steroides
FR2383185A1 (cg-RX-API-DMAC10.html)
ES8103030A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.
ES8703464A1 (es) Procedimiento para preparar pirazol (3,4-b) piridinamidas.
FR2405942A1 (fr) Procede d'obtention du 3-oxa-tricyclo (6.2.1.02,7) undecane-4-one et son utilisation a titre d'agent parfumant
NZ195147A (en) N-(1-alkoxycarbonylethyl)isoxazolylcarboxylic acid anilides
SE7702130L (sv) Forfarande for framstellning av n-(merkaptoacyl)-histidiner
FR2381746A1 (fr) Nouveaux derives encephaliniques a la methionine
ES8201563A1 (es) Un procedimiento para la preparacion de compuestos heteroci-clicos
DK377687A (da) Triazol-fungicidpraeparater
FR2367761A1 (fr) Derives piperidylideniques de benzo-xanthenes,
ES458237A1 (es) Un procedimiento para la preparacion de nuevas iminas.
FR2452925A1 (fr) Composition pharmaceutique contenant un compose 1,3-5 substitue du biuret
SE420888B (sv) Anvendning av vissa pyrazoliumsalter som fungicider
GB1041342A (en) New pyridine derivatives
FR2426673A1 (fr) Pesticides du type pyrethrine
FR2377378A1 (fr) Nouvelles amidines
GB986365A (en) New 3ª‰-phenyl-granatane derivatives
ES457696A1 (es) Un procedimiento mejorado para preparar un compuesto de prostaglandina opticamente activo.
ES476405A1 (es) Un metodo para la preparacion de 2-metiltio-6-fluoro-9-(1- metil-4-piperilideno)-tioxanteno

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303